Inspire Medical Systems, Inc. INSP
We take great care to ensure that the data presented and summarized in this overview for Inspire Medical Systems, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSP
View all-
Vanguard Group Inc Valley Forge, PA3.23MShares$446 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.86MShares$257 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.52MShares$211 Million1.38% of portfolio
-
Dragoneer Investment Group, LLC San Francisco, CA1.3MShares$180 Million5.43% of portfolio
-
Baillie Gifford & CO1.16MShares$160 Million0.17% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.11MShares$154 Million0.05% of portfolio
-
State Street Corp Boston, MA1.01MShares$139 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA859KShares$119 Million0.03% of portfolio
-
William Blair Investment Management, LLC Chicago, IL693KShares$95.9 Million0.34% of portfolio
-
Janus Henderson Group PLC London, X0643KShares$88.9 Million0.06% of portfolio
Latest Institutional Activity in INSP
Top Purchases
Top Sells
About INSP
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Insider Transactions at INSP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 19
2025
|
John Rondoni Officer |
SELL
Open market or private sale
|
Direct |
1,734
-11.19%
|
$258,366
$149.38 P/Share
|
|
May 02
2025
|
Shawn Mc Cormick Director |
SELL
Open market or private sale
|
Direct |
360
-1.48%
|
$57,600
$160.0 P/Share
|
|
May 02
2025
|
Georgia Melenikiotou Director |
SELL
Payment of exercise price or tax liability
|
Direct |
35
-0.96%
|
-
|
|
May 01
2025
|
Gary Lee Ellis Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+17.76%
|
-
|
|
May 01
2025
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+27.33%
|
-
|
|
May 01
2025
|
Shawn Mc Cormick Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+4.93%
|
-
|
|
May 01
2025
|
Shelley G. Broader Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+24.16%
|
-
|
|
May 01
2025
|
Dana G Mead Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+5.29%
|
-
|
|
May 01
2025
|
Casey M Tansey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+5.47%
|
-
|
|
May 01
2025
|
Georgia Melenikiotou Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+25.7%
|
-
|
|
May 01
2025
|
Cynthia Burks Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,266
+32.32%
|
-
|
|
Apr 14
2025
|
Shelley G. Broader Director |
BUY
Grant, award, or other acquisition
|
Direct |
116
+4.11%
|
$17,284
$149.7 P/Share
|
|
Apr 14
2025
|
Georgia Melenikiotou Director |
BUY
Grant, award, or other acquisition
|
Direct |
102
+4.08%
|
$15,198
$149.7 P/Share
|
|
Apr 14
2025
|
Gary Lee Ellis Director |
BUY
Grant, award, or other acquisition
|
Direct |
169
+3.55%
|
$25,181
$149.7 P/Share
|
|
Apr 14
2025
|
Casey M Tansey Director |
BUY
Grant, award, or other acquisition
|
Direct |
103
+0.5%
|
$15,347
$149.7 P/Share
|
|
Mar 03
2025
|
John Rondoni Officer |
SELL
Open market or private sale
|
Direct |
2,287
-12.86%
|
$423,095
$185.6 P/Share
|
|
Mar 03
2025
|
Randy Ban Officer |
SELL
Open market or private sale
|
Direct |
3,947
-13.29%
|
$734,142
$186.22 P/Share
|
|
Feb 24
2025
|
Randy Ban Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,205
-16.44%
|
$410,130
$186.45 P/Share
|
|
Feb 24
2025
|
Randy Ban Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,152
+31.45%
|
-
|
|
Feb 24
2025
|
Richard Buchholz Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,200
-5.74%
|
$409,200
$186.45 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 106K shares |
|---|---|
| Exercise of conversion of derivative security | 68.2K shares |
| Bona fide gift | 500 shares |
| Payment of exercise price or tax liability | 18.6K shares |
|---|---|
| Open market or private sale | 70.1K shares |
| Bona fide gift | 3.5K shares |
| Other acquisition or disposition | 61.8K shares |